Brent J. Barber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Brent J. Barber has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
F. John Meaney
2 shared publicationsAnjan S. Batra
1 shared publicationAshley Gray
1 shared publicationBrandon T. Larsen
Pathology
1 shared publicationBrian Blair
Arizona Pediatric Cardiology Consultants, Tucson, Ariz, USA
1 shared publicationChelsea L. Ihnat
Departments of Pediatrics, University of Arizona, College of Medicine, Tucson, AZ 85724, USA
1 shared publication
Latest Publications
- 1 October 2013
- Published by Elsevier in The Journal of Pediatrics
- Vol. 163 (4) , 1080-1084.e1
Oral Corticosteroids and Onset of Cardiomyopathy in Duchenne Muscular Dystrophy
- 1 October 2013
- Published by Elsevier in The Journal of Pediatrics
- Vol. 163 (4) , 1080-1084.e1
Oral Corticosteroids and Onset of Cardiomyopathy in Duchenne Muscular Dystrophy
- 16 May 2013
- Published by Springer Nature in Pediatric Cardiology
- Vol. 34 (8) , 1803-1807
Feasibility of Pulse Oximetry Screening for Critical Congenital Heart Disease at 2643-Foot Elevation
To evaluate the feasibility of implementing a pulse oximetry screening protocol at a city of mild elevation with a specific focus on the false-positive screening rate. Pulse oximetry screening was performed according to the proposed guidelines endorsed by the American Academy of Pediatrics at a center in Tucson, AZ, at an elevation of 2,643 ft (806 m). During a 10-month period in 2012, 1069 full-term asymptomatic newborns were screened ≥24 h after birth. The mean preductal oxygen saturation was 98.5 ± 1.3 % (range 92–100 %), and the mean postductal oxygen saturation was 98.6 ± 1.3 % (range 94–100 %). Of 1,069 patients screened, 7 were excluded secondary to protocol violations, and 1 screened positive. An echocardiogram was performed on the newborn with the positive screen, and it was normal with the exception of right-to-left shunting across a patent foramen ovale. The false-positive rate was 1/1,062 or 0.094 %. The pulse oximetry screening guidelines recommended by the American Academy of Pediatrics are feasible at an elevation of 2,643 ft (806 m) with a low false-positive rate. Adjustments to the protocol are not required for centers at elevations ≤2,643 ft. Future studies at greater elevations are warranted.
- 16 May 2013
- Published by Springer Nature in Pediatric Cardiology
- Vol. 34 (8) , 1803-1807
Feasibility of Pulse Oximetry Screening for Critical Congenital Heart Disease at 2643-Foot Elevation
To evaluate the feasibility of implementing a pulse oximetry screening protocol at a city of mild elevation with a specific focus on the false-positive screening rate. Pulse oximetry screening was performed according to the proposed guidelines endorsed by the American Academy of Pediatrics at a center in Tucson, AZ, at an elevation of 2,643 ft (806 m). During a 10-month period in 2012, 1069 full-term asymptomatic newborns were screened ≥24 h after birth. The mean preductal oxygen saturation was 98.5 ± 1.3 % (range 92–100 %), and the mean postductal oxygen saturation was 98.6 ± 1.3 % (range 94–100 %). Of 1,069 patients screened, 7 were excluded secondary to protocol violations, and 1 screened positive. An echocardiogram was performed on the newborn with the positive screen, and it was normal with the exception of right-to-left shunting across a patent foramen ovale. The false-positive rate was 1/1,062 or 0.094 %. The pulse oximetry screening guidelines recommended by the American Academy of Pediatrics are feasible at an elevation of 2,643 ft (806 m) with a low false-positive rate. Adjustments to the protocol are not required for centers at elevations ≤2,643 ft. Future studies at greater elevations are warranted.
- 21 March 2011
- Published by Tech Science Press in Congenital Heart Disease
- Vol. 6 (3) , 234-240
Left Ventricular Assist Device Support as a Bridge to Recovery in Young Children
Left ventricular assist device (LVAD) experience and follow-up data in children are limited. We report the deployment and successful weaning from LVAD in young children with severe heart failure (HF). From 2004--2009, 13 children suffering from HF were placed on LVAD. All presented with a dilated left ventricle (LV) with severely reduced contractility, secondary to myocarditis, atrial arrhythmia or idiopathic HF. This study reports their outcomes and longitudinal follow-up. Of 13 young children with HF (ages 1 month--6 years; mean 19.2 months) placed on LVAD: eight weaned to recovery and successful hospital discharge, one was transplanted and four died. Echo follow-up in the weaned patients (mean age 22.1 months) revealed significant improvements from pre-LVAD measurements: LV end-diastolic dimension (LVED) mean z-score decreased from +4.8 to +0.95 (P < .001); fractional shortening (FS %) improved from a mean of 9.3% to 33% (P < .001); and the degree of mitral regurgitation (MR) significantly improved (P < .05). Time to LVAD deployment from HF diagnosis was more likely to be less than 30 days in the successfully weaned patients (100%) than patients who died or were transplanted (20%); P = .007. LVAD support can be utilized as a bridge to recovery in young children with HF. Following LVAD weaning, children sustain improvements in LV size, function and degree of MR. LVAD deployment less than 30 days from HF diagnosis improves the likelihood of successful weaning and illustrates that children with acute etiologies of HF are more likely to achieve recovery.
- 21 March 2011
- Published by Tech Science Press in Congenital Heart Disease
- Vol. 6 (3) , 234-240
Left Ventricular Assist Device Support as a Bridge to Recovery in Young Children
Left ventricular assist device (LVAD) experience and follow-up data in children are limited. We report the deployment and successful weaning from LVAD in young children with severe heart failure (HF). From 2004--2009, 13 children suffering from HF were placed on LVAD. All presented with a dilated left ventricle (LV) with severely reduced contractility, secondary to myocarditis, atrial arrhythmia or idiopathic HF. This study reports their outcomes and longitudinal follow-up. Of 13 young children with HF (ages 1 month--6 years; mean 19.2 months) placed on LVAD: eight weaned to recovery and successful hospital discharge, one was transplanted and four died. Echo follow-up in the weaned patients (mean age 22.1 months) revealed significant improvements from pre-LVAD measurements: LV end-diastolic dimension (LVED) mean z-score decreased from +4.8 to +0.95 (P < .001); fractional shortening (FS %) improved from a mean of 9.3% to 33% (P < .001); and the degree of mitral regurgitation (MR) significantly improved (P < .05). Time to LVAD deployment from HF diagnosis was more likely to be less than 30 days in the successfully weaned patients (100%) than patients who died or were transplanted (20%); P = .007. LVAD support can be utilized as a bridge to recovery in young children with HF. Following LVAD weaning, children sustain improvements in LV size, function and degree of MR. LVAD deployment less than 30 days from HF diagnosis improves the likelihood of successful weaning and illustrates that children with acute etiologies of HF are more likely to achieve recovery.
- 11 June 2007
- Published by Springer Nature in Pediatric Cardiology
- Vol. 28 (4) , 247-249
The Dicrotic Pulse: A Common, Non-Ominous Finding After the Ross Operation
- 11 June 2007
- Published by Springer Nature in Pediatric Cardiology
- Vol. 28 (4) , 247-249
The Dicrotic Pulse: A Common, Non-Ominous Finding After the Ross Operation